Perinatal transmission of bloodborne infections: Difference between revisions
From IDWiki
(→) |
(→: moved to separate pages) |
||
Line 84: | Line 84: | ||
== Hepatitis B virus == |
== Hepatitis B virus == |
||
* [[Hepatitis B in pregnancy#Management|Management of the mother]] |
|||
=== Background === |
|||
* [[Neonatal HBV#Prevention|Management of the neonate]] |
|||
* Pregnant women are screened with HBsAg for active infection, usually during the first trimester |
|||
* Transmission mostly occurs intrapartum, and is highest if they have acute infection in the third trimester |
|||
=== Management === |
|||
==== Antepartum management ==== |
|||
* [[Tenofovir]] is safe in pregnancy; [[lamivudine]] and [[telbivudine]] are alternatives |
|||
* Treatment is started if the viral load is greater than 200,000 copies/mL at 28-32 weeks gestation, and continued until delivery |
|||
==== Peripartum management ==== |
|||
* Prophylaxis should be considered it mother has active hepatitis B (i.e. HBsAg positive), or her status is unknown |
|||
** If status is unknown, try to get HBsAg done STAT (but often not possible) |
|||
* Prophylaxis is with [[hepatitis B immune globulin]] (HBIG) and [[hepatitis B vaccine]] given within 12 hours of life into different limbs |
|||
** Vaccine prevents about 90% of infections, with HBIG adding a bit more |
|||
** HBIG can be given up to 7 days of life but is most effective when given earlier |
|||
* Despite optimal treatment, there is still a 2% risk of vertical transmission |
|||
==== Postpartum management ==== |
|||
* Complete a routine vaccination schedule for hepatitis B in the infant |
|||
** If the birth weight is less than 2000 g, this birth dose should not count towards their vaccine series |
|||
* Check infant serology for HBsAb and HBsAg at 9 to 12 months |
|||
** Maternal HBcAb may be detected up to 24 months post-partum and should not be tested |
|||
* Remember to screen other family members for [[hepatitis B]] |
|||
* Recommend breastfeeding, since hepatitis B is not a contraindication |
|||
=== Further Reading === |
|||
* Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. ''MMWR Recomm Rep''. 2018;67(RR-1):1–31. doi: [https://doi.org/10.15585/mmwr.rr6701a1 10.15585/mmwr.rr6701a1] |
|||
== Hepatitis C virus == |
== Hepatitis C virus == |
Revision as of 15:37, 6 August 2020
Investigations
Unknown maternal serostatus
- If possible, send STAT maternal HIV serology, HBV, HCV, and syphilis; can consider viral load
- For infant:
- At birth send HIV, HBV (sAg, sAb, cAb), HCV-Ab, and syphilis serologies, as well as an HIV PCR (not viral load)
- Repeat HIV PCR at 1, 2, and 4-6 months
HIV
Diagnosis
- Up to 18 months of age, only use HIV PCR
- In general, all infants with perinatal exposure should be checked at 14 to 21 days, 1 to 2 months, and 4 to 6 months
- If high risk, can also check at birth and 2 to 4 weeks after stopping antiretrovirals
- Confirm a positive result with repeat testing
- Serology can be tested starting at 18 to 24 months
Management
Antepartum management
- See HIV in pregnancy for management of an HIV-positive mother
- Note that integrase inhibitors are effective for achieving fast viral suppression
Peripartum management
- Immediate management depends on maternal viral load and treatment status
- In general, a mom with HIV should get IV zidovudine during labour
- If it is unavailable or resistant, could use any pregnancy-safe medication
VL | Antenatal Rx | C-section | Neonatal Rx |
---|---|---|---|
>1000 | Any | Yes | ART |
40-999 | None | Yes | ART |
40-999 | ART | Maybe | ART |
<40 | None | Maybe | ART |
<40 | ART | No | Zidovudine x4 weeks |
Unknown | None | Maybe | ART |
Unknown | ART | Maybe | Unclear |
Selection of antiretrovirals
- Can either do a prophylactic regimen, or treat empirically
- Prophylaxis:
- ZDV/NVP: zidovudine x6 weeks, plus nevirapine x3 in the first week of life
- Empiric treatment:
- ZDV/3TC/NVP: zidovudine for 6 weeks, plus lamivudine and nevirapine for 2 to 6 weeks (preferred)
- ZDV/3TC/RAL: zidovudine for 6 weeks, plus lamivudine and raltegravir for 2 to 6 weeks
- Regarding duration, in the UK they typically treat for 2 weeks while in Canada it is typically 4 weeks
Follow-up
Age | Investigations | Management |
---|---|---|
Birth | CBC/diff, ALT, lactate, and HIV PCR | Start ART as described below |
7 days | CBC/diff, nevirapine level | Dose-adjust nevirapine if needed |
14 days | CBC/diff, nevirapine level, and HIV PCR | Dose-adjust nevirapine if needed |
4 weeks | CBC/diff and ALT; ?HIV PCR? | Stop nevirapine if prior HIV PCR is negative, and continue other ART |
6 weeks | ?HIV PCR? | Stop zidovudine and lamivudine if HIV PCR has been negative |
2 months | Review as needed | |
6 months | CBC/diff and ALT | |
18 months | HIV serology | Developmental assessment |
3.5 years | Developmental assessment | |
5.5 years | Developmental assessment |
Breastfeeding
- Generally recommend against breastfeeding for HIV-positive mothers in Canada, even if HIV is well-controlled
- 10-20% risk if breastfeeding and uncontrolled; less than 1% if fully and reliably suppressed
- As well as risk of HIV transmission, it could theoretically expose child's HIV to low-level antivirals which could induce resistance
Hepatitis B virus
Hepatitis C virus
- About 5% risk of vertical transmission, though higher if coinfected with HIV
- About half are transmitted antepartum and half intrapartum
- Not urgent, as it is a chronic illness that may not manifest for decades
- Serology to be done at 12-18 months for diagnosis
- If significant anxiety, can send HCV-PCR at 3 to 6 months
- 25-30% will spontaneous clear it
- Still need serology at 12-18 months, and repeat PCR around 18 months